Drugs / Osteodex
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01595087 | Jan 2012 → Jun 2013 | metastatic prostate carcinoma | DexTech Medical AB | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02825628 | May 2016 → Jun 2018 | metastatic prostate carcinoma | DexTech Medical AB | Completed | No outcome recorded |
| Phase 2 | NCT02378870 | Jan → Jun 2015 | metastatic prostate carcinoma | DexTech Medical AB | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osteodex | “Osteodex is a poly-bisphosphonate containing three known substances; dextran, alendronate and guanidine.” NCT01595087 ↗ |
| Modality | Other / unclassified | “Osteodex is a poly-bisphosphonate containing three known substances; dextran, alendronate and guanidine.” NCT02378870 ↗ |
| Route | Intravenous | “route of administration: intravenous infusion” NCT02825628 ↗ |